News
MIRA
0.7526
0.00%
0.0000
Weekly Report: what happened at MIRA last week (0907-0911)?
Weekly Report · 1d ago
Weekly Report: what happened at MIRA last week (0831-0904)?
Weekly Report · 09/07 09:32
Psychedelic: Clearmind initiates Phase IIa of CMND-100 trial
TipRanks · 09/03 14:05
Short Interest Alert: Most and least shorted sub-$2B healthcare stocks in Aug 2026
Seeking Alpha · 09/02 14:15
Why Is MIRA Pharmaceuticals Stock Gaining Tuesday?
Benzinga · 09/01 17:12
12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga · 09/01 17:07
MIRA-55 toxicology results advance non-opioid pain program
TipRanks · 09/01 12:27
Mira Pharmaceuticals announces results from MIRA-55 studies
TipRanks · 09/01 12:20
Weekly Report: what happened at MIRA last week (0824-0828)?
Weekly Report · 08/31 09:35
Weekly Report: what happened at MIRA last week (0817-0821)?
Weekly Report · 08/24 09:35
Weekly Report: what happened at MIRA last week (0810-0814)?
Weekly Report · 08/17 09:36
Weekly Report: what happened at MIRA last week (0803-0807)?
Weekly Report · 08/10 09:33
MIRA Pharmaceuticals Reports Positive Toxicokinetic Data For SKNY-1 In Obesity
NASDAQ · 08/08 21:48
Mira reports positive results in 7-day dog study for obesity candidate SKNY-1
TipRanks · 08/06 13:38
MIRA Reports Positive Preclinical Results for Obesity Candidate SKNY-1
TipRanks · 08/06 12:42
12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga · 08/03 21:05
Weekly Report: what happened at MIRA last week (0727-0731)?
Weekly Report · 08/03 09:33
MIRA Pharmaceuticals Receives Nasdaq Minimum Bid Price Notice
TipRanks · 07/31 21:33
Mira Pharmaceuticals provides update on MIRA-55, SKNY-1
TipRanks · 07/30 13:36
Weekly Report: what happened at MIRA last week (0720-0724)?
Weekly Report · 07/27 09:35
More
Webull provides a variety of real-time MIRA stock news. You can receive the latest news about Mira Pharma through multiple platforms. This information may help you make smarter investment decisions.
About MIRA
MIRA Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of therapeutics for neurologic, neuropsychiatric, and metabolic disorders. The Company's pipeline includes oral drug candidates designed to address significant unmet medical needs in neuropathic pain, inflammatory pain, obesity, addiction, anxiety, and cognitive decline. It holds exclusive license rights in the United States, Canada and Mexico for Ketamir-2 and MIRA-55, two novel drug candidates designed to address unmet medical needs in neuropathic and inflammatory pain, as well as neuropsychiatric and neurocognitive disorders. Its pipeline also includes SKNY-1, a next-generation oral therapy candidate for obesity and smoking cessation. Ketamir-2 is a patent-pending oral ketamine analog evaluated for the treatment of diabetic neuropathy and is in an ongoing Phase I clinical trial.